Emibetuzumab, formerly known as LY2875358, represents a novel therapeutic approach in oncology, specifically targeting the HGF Receptor tyrosine kinase. This engineered immunoglobulin operates by specifically binding https://www.targetmol.com/compound/emibetuzumab